Barry Quart Sells 2,602 Shares of Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Director Barry Quart sold 2,602 shares of the firm’s stock in a transaction on Wednesday, February 4th. The stock was sold at an average price of $45.02, for a total value of $117,142.04. Following the completion of the sale, the director directly owned 12,546 shares of the company’s stock, valued at $564,820.92. This trade represents a 17.18% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Kiniksa Pharmaceuticals International Trading Down 2.2%

Shares of KNSA opened at $42.58 on Friday. Kiniksa Pharmaceuticals International, plc has a 12-month low of $18.12 and a 12-month high of $45.50. The firm has a market capitalization of $3.23 billion, a P/E ratio of 94.62 and a beta of 0.06. The firm has a 50-day moving average price of $41.80 and a 200 day moving average price of $38.13.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last issued its earnings results on Tuesday, October 28th. The company reported $0.23 EPS for the quarter, missing analysts’ consensus estimates of $0.31 by ($0.08). Kiniksa Pharmaceuticals International had a return on equity of 7.46% and a net margin of 6.01%.The firm had revenue of $180.86 million for the quarter, compared to analysts’ expectations of $166.64 million. During the same period last year, the firm earned ($0.18) earnings per share. Kiniksa Pharmaceuticals International’s revenue for the quarter was up 61.2% on a year-over-year basis. Equities research analysts predict that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on KNSA shares. Wall Street Zen cut Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a research note on Sunday, November 2nd. The Goldman Sachs Group raised their price objective on Kiniksa Pharmaceuticals International from $45.00 to $55.00 and gave the stock a “buy” rating in a research report on Wednesday, October 29th. Weiss Ratings restated a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a report on Thursday, January 22nd. Zacks Research lowered shares of Kiniksa Pharmaceuticals International from a “hold” rating to a “strong sell” rating in a research note on Tuesday, January 13th. Finally, Citigroup lifted their price target on shares of Kiniksa Pharmaceuticals International from $45.00 to $50.00 and gave the company a “buy” rating in a research report on Friday, October 17th. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $52.33.

Institutional Trading of Kiniksa Pharmaceuticals International

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Savant Capital LLC acquired a new stake in shares of Kiniksa Pharmaceuticals International in the second quarter valued at $398,000. Y Intercept Hong Kong Ltd purchased a new stake in Kiniksa Pharmaceuticals International during the 2nd quarter worth about $1,648,000. Asset Management One Co. Ltd. increased its holdings in Kiniksa Pharmaceuticals International by 624.2% during the 2nd quarter. Asset Management One Co. Ltd. now owns 13,470 shares of the company’s stock worth $373,000 after purchasing an additional 11,610 shares during the period. Franklin Resources Inc. raised its position in Kiniksa Pharmaceuticals International by 62.2% in the 2nd quarter. Franklin Resources Inc. now owns 108,574 shares of the company’s stock valued at $3,004,000 after purchasing an additional 41,632 shares in the last quarter. Finally, Campbell & CO Investment Adviser LLC purchased a new position in shares of Kiniksa Pharmaceuticals International in the 3rd quarter valued at about $1,480,000. 53.95% of the stock is currently owned by hedge funds and other institutional investors.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.